These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 15262305)

  • 21. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.
    Ferenczi K; Yawalkar N; Jones D; Kupper TS
    Arch Dermatol; 2003 Jul; 139(7):909-13. PubMed ID: 12873887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
    Singh F; Lebwohl MG
    J Am Acad Dermatol; 2004 Oct; 51(4):570-3. PubMed ID: 15389192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current therapy concepts in cutaneous T-cell lymphomas].
    Nestle FO; Häffner AC; Schmid MH; Dummer R; Burg G
    Schweiz Med Wochenschr; 1997 Feb; 127(8):311-20. PubMed ID: 9157537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB.
    D'Acunto C; Gurioli C; Neri I
    J Dermatolog Treat; 2010 Jan; 21(1):45-8. PubMed ID: 19603308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of maintenance phototherapy in cutaneous T-cell lymphoma.
    Pothiawala SZ; Baldwin BT; Cherpelis BS; Glass LF; Fenske NA
    J Drugs Dermatol; 2010 Jul; 9(7):800-3. PubMed ID: 20677536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
    Kannangara AP; Levitan D; Fleischer AB
    J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination treatment modalities in cutaneous T-cell lymphoma (CTCL).
    Guitart J
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S17-20. PubMed ID: 16516671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durable complete remission of therapy-refractory, tumor-stage cutaneous T-cell lymphoma under radioimmunotherapy with electron beam irradiation and denileukin diftitox.
    Wobser M; Göppner D; Lang SC; Beckmann G; Flentje M; Ugurel S; Bröcker EB; Becker JC
    Arch Dermatol; 2010 Jul; 146(7):805-6. PubMed ID: 20644054
    [No Abstract]   [Full Text] [Related]  

  • 29. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
    Geskin L
    Skin Therapy Lett; 2007 Jun; 12(5):1-4. PubMed ID: 17609808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutaneous T-cell lymphomas: a review with emphasis on new treatment approaches.
    Querfeld C; Rosen ST; Kuzel TM; Guitart J
    Semin Cutan Med Surg; 2003 Sep; 22(3):150-61. PubMed ID: 14649582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL).
    Dummer R
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S33-6. PubMed ID: 16516674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Skin directed therapy for mycosis fungoides: a review.
    Berthelot C; Rivera A; Duvic M
    J Drugs Dermatol; 2008 Jul; 7(7):655-66. PubMed ID: 18664158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma.
    Shapiro M; Rook AH; Lehrer MS; Junkins-Hopkins JM; French LE; Vittorio CC
    J Am Acad Dermatol; 2002 Dec; 47(6):956-61. PubMed ID: 12451388
    [No Abstract]   [Full Text] [Related]  

  • 34. Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma.
    Ramsay DL; Lish KM; Yalowitz CB; Soter NA
    Arch Dermatol; 1992 Jul; 128(7):931-3. PubMed ID: 1626959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutaneous T-cell lymphoma: overview and nursing perspectives.
    McCann SA
    Nurs Clin North Am; 2007 Sep; 42(3):421-55, vi-vii. PubMed ID: 17825663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis.
    Rook AH; Wood GS; Duvic M; Vonderheid EC; Tobia A; Cabana B
    J Am Acad Dermatol; 2010 Dec; 63(6):984-90. PubMed ID: 20889234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience.
    Siakantaris MP; Tsirigotis P; Stavroyianni N; Argyropoulos KV; Girkas K; Pappa V; Chondropoulos S; Papadavid E; Sakellari I; Anagnostopoulos A; Antoniou C; Dervenoulas J
    Transfus Apher Sci; 2012 Apr; 46(2):189-93. PubMed ID: 22178592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
    Duvic M
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of the primary cutaneous lymphomas.
    Prince HM; McCormack C; Ryan G; O'Keefe R; Seymour JF; Baker C
    Australas J Dermatol; 2003 Nov; 44(4):227-40; quiz 241-2. PubMed ID: 14616487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Triple secondary malignancy of gingiva, palate and esophagus after an allogeneic bone marrow transplantation for cutaneous T-cell lymphoma].
    Koharazawa H; Yamaji S; Takasaki H; Takabayashi M; Fujimaki K; Taguchi J; Kanamori H; Ishigatsubo Y
    Rinsho Ketsueki; 2005 Jul; 46(7):496-500. PubMed ID: 16440741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.